标题
Anticalin® Proteins as Therapeutic Agents in Human Diseases
作者
关键词
-
出版物
BIODRUGS
Volume 32, Issue 3, Pages 233-243
出版商
Springer Nature
发表日期
2018-05-10
DOI
10.1007/s40259-018-0278-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models
- (2018) Lars Friedrich et al. BIOLOGICAL CHEMISTRY
- Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey
- (2018) Andreas M Hohlbaum et al. BRITISH JOURNAL OF PHARMACOLOGY
- Targeting the interleukin-4 and interleukin-13 pathways in severe asthma
- (2018) Amit D. Parulekar et al. CURRENT OPINION IN PULMONARY MEDICINE
- Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain–Fused Anticalin Protein
- (2018) Yusuke Masuda et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Anticalins Reveal High Plasticity in the Mode of Complex Formation with a Common Tumor Antigen
- (2018) André Schiefner et al. STRUCTURE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab in the management of moderate-to-severe asthma: the data so far
- (2017) Pilar Barranco et al. Therapeutics and Clinical Risk Management
- High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer -amyloid peptide
- (2016) S. Rauth et al. BIOCHEMICAL JOURNAL
- Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
- (2016) Iain C. Macdougall et al. KIDNEY INTERNATIONAL
- Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA)
- (2016) Cyril Barinka et al. PROTEIN ENGINEERING DESIGN & SELECTION
- The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds
- (2015) André Schiefner et al. ACCOUNTS OF CHEMICAL RESEARCH
- Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
- (2015) Hendrik Gille et al. ANGIOGENESIS
- Managing unwanted immunogenicity of biologicals
- (2015) Maureen Deehan et al. AUTOIMMUNITY REVIEWS
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- The Labile Side of Iron Supplementation in CKD
- (2015) I. Slotki et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
- (2015) Marlon J Hinner et al. Journal for ImmunoTherapy of Cancer
- Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
- (2014) David A Schaer et al. Journal for ImmunoTherapy of Cancer
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
- (2013) Q. Ye et al. CLINICAL CANCER RESEARCH
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
- (2013) K. F. Chung et al. EUROPEAN RESPIRATORY JOURNAL
- Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins
- (2013) A. Richter et al. FEBS LETTERS
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
- (2013) Jessica Ann Chacon et al. PLoS One
- First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
- (2013) Klaus Mross et al. PLoS One
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal Fibronectin
- (2012) Michaela Gebauer et al. JOURNAL OF MOLECULAR BIOLOGY
- Abstract A212: First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study.
- (2012) K. Mross et al. MOLECULAR CANCER THERAPEUTICS
- Hepcidin and Disorders of Iron Metabolism
- (2010) Tomas Ganz et al. Annual Review of Medicine
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- High-throughput Sorting of an Anticalin Library via EspP-mediated Functional Display on the Escherichia coli Cell Surface
- (2010) Uli Binder et al. JOURNAL OF MOLECULAR BIOLOGY
- Have we overestimated the benefit of human(ized) antibodies?
- (2010) Daniel R. Getts et al. mAbs
- A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity
- (2009) Daniel A. Breustedt et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- High-Affinity Recognition of Lanthanide(III) Chelate Complexes by a Reprogrammed Human Lipocalin 2
- (2009) Hyun Jin Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequent Expression of Glypican-3 in Merkel Cell Carcinoma
- (2008) Huiying He et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now